PMA device
Glaukos Trabecular Micro Bypass Stent Model GTS100R/L
Glaukos Corporation · Intraocular Pressure Lowering Implant (OGO, Class III) · First FDA decision Mar 5, 2013, newest Mar 8, 2013Glaucoma
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
38
Naming "Trabecular Micro Bypass"
MAUDE reports
1,397
Brand "Trabecular Micro Bypass", since 2015
PubMed studies
157
Mentioning "Trabecular Micro Bypass"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Glaukos Trabecular Micro Bypass Stent Model GTS100R/L
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- GLAUKOS TRABECULAR MICRO BYPASS STENT MODEL GTS100R/LPMA supplement
P080030-S004 · Decided Mar 8, 2013 · 231 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- GLAUKOS TRABECULAR MICRO BYPASS STENT MODEL GTS100R/LPMA supplement
P080030-S005 · Decided Mar 5, 2013 · 228 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
- GLAUKOS TRABECULAR MICRO BYPASS STENT MODEL GTS100R/LPMA supplement
P080030-S003 · Decided Mar 5, 2013 · 228 days after receipt · Normal 180 Day Track No User Fee
Device type: Intraocular pressure lowering implant (OGO) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational determinationOn the books20.36Updated Oct 6, 2026
- Implantable Pulmonary Artery Pressure Sensors for Heart Failure ManagementNational analysisReview closedCAG-00466NUpdated Sep 18, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Trabecular Micro Bypass", any status and sponsor, newest update first.
- Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle GlaucomaRecruiting
Jonathon MyersAcademic, hospital or other
NCT07228221 · 20 participants (planned) · Start Jan 5, 2026 · Primary completion Aug 30, 2031
Device: iStent infinite trabecular micro-bypass system model iS3 · For: Open Angle Glaucoma; Pigmentary Glaucoma; Pseudoexfoliation Glaucoma
Sites: Philadelphia, Pennsylvania
Sight Sciences, Inc.Not on our public-company list
NCT04658095 · 10 participants · Start Jan 11, 2022 · Primary completion Nov 18, 2022
Device: Canaloplasty and trabeculotomy with the OMNI system.; iStent inject and 1 more · For: Glaucoma, Open-Angle
Sites: Frankfurt, Germany; Barcelona, Spain; Valencia, Spain · 5 sites in all
Yu-Ting TsaoAcademic, hospital or other
NCT06630546 · 71 participants · Start May 16, 2022 · Primary completion Apr 30, 2023
Device: first generation iStent (Glaukos, San Clemente, CA, USA) insertion; phacoemulsification · For: Primary Open Angle Glaucoma (POAG); Istent Inject W; Normal Tension Glaucoma (NTG)
Sites: Taoyuan City, Taiwan
35 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Trabecular Micro Bypass", and for the whole product code for context.
This brand
1,397 reports: 481 malfunction, 916 injury, 0 death
Whole product code OGO
2,634 reports: 667 malfunction, 1,967 injury, 0 death
Newest reports for this brand
2032546-2026-00100 · Received Oct 30, 2026 · Event dated Oct 9, 2026
Device type: Implant, Eye Valve (KYF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Corneal Edema
- iStent Inject Trabecular Micro-Bypass SystemMalfunction
2032546-2026-00098 · Received Oct 21, 2026 · Event dated Sep 29, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Obstruction of Flow
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2032546-2026-00099 · Received Oct 21, 2026 · Event dated Oct 2, 2026
Device type: Intraocular Pressure Lowering Implant (OGO)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hyphema; Intraocular Pressure Increased
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Trabecular Micro Bypass"[tiab]. The summary above synthesizes these.
- Analyzing the Shortcomings of Trabecular Micro-bypass Stents for Surgical Management of Glaucoma.
Dada T, Beri N · J Curr Glaucoma Pract · 2024Editorial
- Third-Generation Trabecular Micro-Bypass Implantation with Phacoemulsification for Glaucoma.
Vest Z, Alinaghizadeh N, Prendergast C · Ophthalmol Ther · 2025
- [Not Available].
Choo DM, Durham TA, Zhang H, et al. · Graefes Arch Clin Exp Ophthalmol · 2026Comparative Study, English Abstract
- Trabecular micro-bypass stent implantation with cataract extraction in pigmentary glaucoma.
Ferguson TJ, Ibach M, Schweitzer J, et al. · Clin Exp Ophthalmol · 2020
- Third-Generation Trabecular Micro-Bypass Implantation and Phacoemulsification in Patients with Glaucoma: A Multicenter Study.
Shultz M, Vest ZM, Trubnik V, et al. · Vision (Basel) · 2025
- Glaukos iStent Trabecular Micro-Bypass.
Nichamin LD · Middle East Afr J Ophthalmol · 2009
- iStent inject Trabecular Micro-Bypass with or Without Cataract Surgery Yields Sustained 5-Year Glaucoma Control.
Hengerer FH, Auffarth GU, Conrad-Hengerer I · Adv Ther · 2022Research Support, Non-U.S. Gov't
- Trabecular micro-bypass implant (iStent®) in a case of bilateral acute depigmentation of the iris.
Maestrini HA, Maestrini AA, Cenachi SPF, et al. · Arq Bras Oftalmol · 2022Letter
- iStent Trabecular Micro-bypass Stent Implantation Combined with Phacoemulsification for Open-Angle Glaucoma: A 2-Year Post-marketing Surveillance Study in Japan.
Inatani M, Kohama I, Chu A · Adv Ther · 2022Observational Study, Research Support, Non-U.S. Gov't
- Refractive outcomes of toric intraocular lens in combined trabecular micro bypass stent implantation and cataract surgery in glaucomatous eyes.
López-Caballero C, Sánchez-Sánchez C, Puerto B, et al. · Int Ophthalmol · 2022
- Effectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma.
Sarkisian SR, Grover DS, Gallardo MJ, et al. · J Glaucoma · 2023Multicenter Study
- Adverse events of trabecular micro-bypass minimally invasive glaucoma surgery devices: a five-year analysis from the FDA MAUDE database.
Hawas Y, Ghazou A, Gerges MW, et al. · Int Ophthalmol · 2025
Other devices of this type
Also filed under product code OGO.
- iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular MiGlaukos Corporation · PMA 2022
- iStent inject Trabecular MicroBypass SystemGlaukos Corporation · PMA 2025
- Hydrus MicrostentAlcon Research, LLC · PMA 2025
- iStent inject® W Trabecular Micro-Bypass System Model iS2Glaukos Corporation · PMA 2025
- CyPass System 241-SAlcon Research, Ltd. · PMA 2018
- CyPass Micro-StentAlcon Research, Ltd. · PMA 2020
- iStent® Trabecular Mjcro-Bypass Stent System, Model GTS100Glaukos Corporation · PMA 2024
- Hydrus MicrosentAlcon Research, LLC · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.